CONTEXT: Posttransplantation diabetes mellitus (PTDM) is a major metabolic complication in renal transplant recipients. Adiponectin (ADIPOQ) and adiponectin receptor-1 (ADIPOR1) gene polymorphisms have been associated with type 2 diabetes. However, it is unknown whether these polymorphisms are also risk factors for PTDM. OBJECTIVE: We investigated the association between PTDM and single-nucleotide polymorphisms of ADIPOQ and ADIPOR1 in a cohort of renal allograft recipients. DESIGN, SETTING, AND PARTICIPANTS: Five hundred seventy-five patients (367 men and 208 women) who received kidney transplants between 1989 and 2007, without a history of diabetes and with a pretransplant fasting glucose concentration less than 5.5 mmol/liter. Patients were followed up for a median 10 yr. Genotypes included single-nucleotide polymorphisms of the following: ADIPOQ rs266729, rs822395, rs822396, rs2241766, and rs1501299 and ADIPOR1 rs2232853, rs12733285, and rs1342387. RESULTS: TT-homozygotes in ADIPOQ rs1501299 [hazard ratio (HR) = 1.70, P = 0.032] had greater risk of PTDM after adjusting for age, sex, amount of weight gain, and type of immunosuppressant. There was a significant interaction between sex and ADIPOQ rs1501299 genotype (P = 0.037). In men, but not in women, TT-homozygotes in ADIPOQ rs1501299 were more likely to develop PTDM than the wild GG-homozygotes (HR = 2.50, P = 0.002), whereas GT-heterozygotes had nonsignificantly elevated risk (HR = 1.41, P = 0.128). CONCLUSION: Genetic variation in ADIPOQ rs1501299 is associated with PTDM in a sex-specific manner.
CONTEXT: Posttransplantation diabetes mellitus (PTDM) is a major metabolic complication in renal transplant recipients. Adiponectin (ADIPOQ) and adiponectin receptor-1 (ADIPOR1) gene polymorphisms have been associated with type 2 diabetes. However, it is unknown whether these polymorphisms are also risk factors for PTDM. OBJECTIVE: We investigated the association between PTDM and single-nucleotide polymorphisms of ADIPOQ and ADIPOR1 in a cohort of renal allograft recipients. DESIGN, SETTING, AND PARTICIPANTS: Five hundred seventy-five patients (367 men and 208 women) who received kidney transplants between 1989 and 2007, without a history of diabetes and with a pretransplant fasting glucose concentration less than 5.5 mmol/liter. Patients were followed up for a median 10 yr. Genotypes included single-nucleotide polymorphisms of the following: ADIPOQrs266729, rs822395, rs822396, rs2241766, and rs1501299 and ADIPOR1rs2232853, rs12733285, and rs1342387. RESULTS: TT-homozygotes in ADIPOQrs1501299 [hazard ratio (HR) = 1.70, P = 0.032] had greater risk of PTDM after adjusting for age, sex, amount of weight gain, and type of immunosuppressant. There was a significant interaction between sex and ADIPOQrs1501299 genotype (P = 0.037). In men, but not in women, TT-homozygotes in ADIPOQrs1501299 were more likely to develop PTDM than the wild GG-homozygotes (HR = 2.50, P = 0.002), whereas GT-heterozygotes had nonsignificantly elevated risk (HR = 1.41, P = 0.128). CONCLUSION: Genetic variation in ADIPOQrs1501299 is associated with PTDM in a sex-specific manner.
Authors: Phuong-Thu T Pham; Phuong-Chi T Pham; Gerald S Lipshutz; Alan H Wilkinson Journal: Endocrinol Metab Clin North Am Date: 2007-12 Impact factor: 4.741
Authors: Teresa Soccio; Yuan-Yuan Zhang; Simonetta Bacci; Wojciech Mlynarski; Grzegorz Placha; Greer Raggio; Rosa Di Paola; Antonella Marucci; Michael T Johnstone; Ernest V Gervino; Nada A Abumrad; Samuel Klein; Vincenzo Trischitta; Alessandro Doria Journal: Diabetes Date: 2006-10 Impact factor: 9.461
Authors: Jessica G Woo; Lawrence M Dolan; Ranjan Deka; Ritesh D Kaushal; Yayun Shen; Prodipto Pal; Stephen R Daniels; Lisa J Martin Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Eun Seok Kang; Myoung Soo Kim; Yu Seun Kim; Kyu Yeon Hur; Seung Jin Han; Chung Mo Nam; Chul Woo Ahn; Bong Soo Cha; Soon Il Kim; Hyun Chul Lee Journal: Diabetes Care Date: 2007-10-12 Impact factor: 19.112
Authors: Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447